当前位置:首页 >财报库 > 报告详情

百时美施贵宝Bristol Myers Squibb(BMY)2025年第一季度财报「NYSE」(英文版)(366页).pdf

上传人: Kell****reet 编号:652441 2025-05-14 366页 2.28MB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549_FORM 10-Q_ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934For

2、 the transition period from _ to _Commission File Number 001-01136_BRISTOL-MYERS SQUIBB COMPANY(Exact name of registrant as specified in its charter)_Delaware 22-0790350(State or other jurisdiction ofincorporation or organization)(I.R.S EmployerIdentification No.)Route 206&Province Line Road,Princet

3、on,New Jersey 08543(Address of principal executive offices)(Zip Code)(609)252-4621(Registrants telephone number,including area code)_(Former name,former address and former fiscal year,if changed since last report)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Sy

4、mbol(s)Name of each exchange on which registeredCommon Stock,$0.10 Par ValueBMYNew York Stock Exchange1.000%Notes due 2025BMY25New York Stock Exchange1.750%Notes due 2035BMY35New York Stock ExchangeCelgene Contingent Value RightsCELG RTNew York Stock ExchangeIndicate by check mark whether the regist

5、rant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 duringthe preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to the filing requirements for thepast 90 days.Yes No

6、Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was required to submit suchfiles

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文是Bristol-Myers Squibb Company(BMS)2025年第一季度10-Q报告的摘录,主要内容包括: 1. 财务数据:2025年第一季度,BMS的总收入为112亿美元,净产品销售额为108亿美元,研发支出为22.6亿美元。 2. 业务合并:BMS在2024年进行了多项业务合并,包括收购Karuna、RayzeBio和Mirati,这些合并增强了BMS在肿瘤学领域的产品组合。 3. 重组计划:BMS在2023年启动了一项重组计划,以加速向患者提供药物,预计总费用约为25亿美元,截至2025年第一季度已发生12亿美元。 4. 法律诉讼:BMS面临多项法律诉讼,包括专利侵权、反垄断、证券、定价、销售和营销实践等,公司正在积极应对这些诉讼。 5. 税收问题:BMS正在接受多个税务机关的审查,包括美国国税局,涉及转移定价和其他税务问题,可能对公司的财务报表产生重大影响。 6. 员工股权计划:2025年第一季度,BMS的股权激励费用为1.44亿美元。 7. 知识产权:BMS在欧洲针对多家寻求在Eliquis化合物专利到期前推出仿制药的公司提起诉讼。
2025年第一季度,百时美施贵宝公司净收入是多少? 百时美施贵宝公司2025年第一季度研发费用是多少? 百时美施贵宝公司2025年第一季度在美国的收入是多少?
客服
商务合作
小程序
服务号
折叠